大便失禁 - 市場洞察，流行病學，市場預測:2034年

未來幾年，由於人們對該疾病的認識不斷提高以及全球醫療保健支出的增加，預計大便失禁市場將發生變化。

公司和研究機構正在努力評估可能影響大便失禁研究和開發的課題並探索機會。正在開發的療法著重於治療/改善疾病狀況的新方法。各大公司都參與開發大便失禁的治療方法。新療法的出現預計將對大便失禁市場產生重大影響。

本報告調查了七個主要國家的大便失禁市場，並提供了市場概況，以及流行病學、患者趨勢、新療法、到 2034 年的市場規模預測以及未滿足的醫療需求。

目錄

第1章 重要的洞察

第2章 大便失禁的摘要整理

第3章 大便失禁的競爭資訊分析

第4章 大便失禁:市場概要

第5章 大便失禁:疾病的背景和概要

• 簡介
• 徵兆與症狀
• 病理學
• 危險因素
• 診斷

第6章 患者趨勢

第7章 大便失禁的流行病學和患者人口

• 流行病學的主要調查結果
• 前提和根據:主要7個國家
• 流行病學Scenario:主要7個國家
• 美國
• 歐洲5個國家
• 日本流行病學

第8章 治療流程，目前治療，醫療行為

第9章 未滿足需求

第10章 大便失禁治療的主要評估項目

第11章 已上市產品

第12章 新治療方法

第13章 市場分析大便失禁:主要7個國家

第14章 屬性分析

第15章 主要7個國家:市場預測

• 美國:市場規模
• 歐洲5個國家:市場規模與展望
• 德國市場規模
• 法國市場規模
• 義大利市場規模
• 西班牙市場規模
• 英國市場規模
• 日本市場規模

第16章 與大便失禁的存取(點閱)償付概要

第17章 KOL的見解

第18章 推動市場要素

第19章 市場障礙

第20章 附錄

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

DelveInsight's "Fecal Incontinence - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Fecal Incontinence, historical and forecasted epidemiology as well as the Fecal Incontinence market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fecal Incontinence market report provides current treatment practices, emerging drugs, Fecal Incontinence market share of the individual therapies, current and forecasted Fecal Incontinence market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Fecal Incontinence treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Fecal Incontinence Disease Understanding and Treatment Algorithm

The DelveInsight Fecal Incontinence market report gives a thorough understanding of the Fecal Incontinence by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Fecal Incontinence.

Treatment

It covers the details of conventional and current medical therapies available in the Fecal Incontinence market for the treatment of the condition. It also provides Fecal Incontinence treatment algorithms and guidelines in the United States, Europe, and Japan.

Fecal Incontinence Epidemiology

The Fecal Incontinence epidemiology division provide insights about historical and current Fecal Incontinence patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Fecal Incontinence epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Fecal Incontinence Epidemiology

The epidemiology segment also provides the Fecal Incontinence epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Fecal Incontinence Drug Chapters

Drug chapter segment of the Fecal Incontinence report encloses the detailed analysis of Fecal Incontinence marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Fecal Incontinence clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Fecal Incontinence treatment.

Fecal Incontinence Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Fecal Incontinence treatment.

Fecal Incontinence Market Outlook

The Fecal Incontinence market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Fecal Incontinence market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Fecal Incontinence market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Fecal Incontinence market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Fecal Incontinence market in 7MM.

The United States Market Outlook

This section provides the total Fecal Incontinence market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Fecal Incontinence market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Fecal Incontinence market size and market size by therapies in Japan is also mentioned.

Fecal Incontinence Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Fecal Incontinence market or expected to get launched in the market during the study period 2020-2034. The analysis covers Fecal Incontinence market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Fecal Incontinence Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Fecal Incontinence key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Fecal Incontinence emerging therapies.

Reimbursement Scenario in Fecal Incontinence

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Fecal Incontinence domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Fecal Incontinence market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Fecal Incontinence Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Fecal Incontinence, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Fecal Incontinence epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Fecal Incontinence are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Fecal Incontinence market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Fecal Incontinence market

Report Highlights:

• In the coming years, Fecal Incontinence market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Fecal Incontinence R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Fecal Incontinence. Launch of emerging therapies will significantly impact the Fecal Incontinence market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Fecal Incontinence
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Fecal Incontinence Report Insights

• Patient Population
• Therapeutic Approaches
• Fecal Incontinence Pipeline Analysis
• Fecal Incontinence Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Fecal Incontinence Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Fecal Incontinence Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Fecal Incontinence Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Fecal Incontinence market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Fecal Incontinence total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Fecal Incontinence market size during the forecast period (2024-2034)?
• At what CAGR, the Fecal Incontinence market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Fecal Incontinence market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Fecal Incontinence market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Fecal Incontinence?
• What is the historical Fecal Incontinence patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Fecal Incontinence in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Fecal Incontinence?
• Out of all 7MM countries, which country would have the highest prevalent population of Fecal Incontinence during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Fecal Incontinence treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Fecal Incontinence in the USA, Europe, and Japan?
• What are the Fecal Incontinence marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Fecal Incontinence?
• How many therapies are developed by each company for Fecal Incontinence treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Fecal Incontinence treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Fecal Incontinence therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fecal Incontinence and their status?
• What are the key designations that have been granted for the emerging therapies for Fecal Incontinence?
• What are the global historical and forecasted market of Fecal Incontinence?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Fecal Incontinence market
• To understand the future market competition in the Fecal Incontinence market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Fecal Incontinence in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Fecal Incontinence market
• To understand the future market competition in the Fecal Incontinence market

Table of Contents

1. Key Insights

2. Executive Summary of Fecal Incontinence

3. Competitive Intelligence Analysis for Fecal Incontinence

4. Fecal Incontinence: Market Overview at a Glance

• 4.1. Fecal Incontinence Total Market Share (%) Distribution in 2020
• 4.2. Fecal Incontinence Total Market Share (%) Distribution in 2034

5. Fecal Incontinence: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Fecal Incontinence Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Fecal Incontinence Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Fecal Incontinence Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Fecal Incontinence Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Fecal Incontinence Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Fecal Incontinence Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Fecal Incontinence Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Fecal Incontinence Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Fecal Incontinence Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Fecal Incontinence Treatment and Management
• 8.2. Fecal Incontinence Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Fecal Incontinence Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Fecal Incontinence: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Fecal Incontinence Market Size in 7MM
• 13.3. Fecal Incontinence Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Fecal Incontinence Total Market Size in the United States
  • 15.1.2. Fecal Incontinence Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Fecal Incontinence Total Market Size in Germany
  • 15.3.2. Fecal Incontinence Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Fecal Incontinence Total Market Size in France
  • 15.4.2. Fecal Incontinence Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Fecal Incontinence Total Market Size in Italy
  • 15.5.2. Fecal Incontinence Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Fecal Incontinence Total Market Size in Spain
  • 15.6.2. Fecal Incontinence Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Fecal Incontinence Total Market Size in the United Kingdom
  • 15.7.2. Fecal Incontinence Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Fecal Incontinence Total Market Size in Japan
  • 15.8.3. Fecal Incontinence Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Fecal Incontinence

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

List of Tables

• Table 1: 7MM Fecal Incontinence Epidemiology (2020-2034)
• Table 2: 7MM Fecal Incontinence Diagnosed and Treatable Cases (2020-2034)
• Table 3: Fecal Incontinence Epidemiology in the United States (2020-2034)
• Table 4: Fecal Incontinence Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Fecal Incontinence Epidemiology in Germany (2020-2034)
• Table 6: Fecal Incontinence Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Fecal Incontinence Epidemiology in France (2020-2034)
• Table 8: Fecal Incontinence Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Fecal Incontinence Epidemiology in Italy (2020-2034)
• Table 10: Fecal Incontinence Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Fecal Incontinence Epidemiology in Spain (2020-2034)
• Table 12: Fecal Incontinence Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Fecal Incontinence Epidemiology in the UK (2020-2034)
• Table 14: Fecal Incontinence Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Fecal Incontinence Epidemiology in Japan (2020-2034)
• Table 16: Fecal Incontinence Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Fecal Incontinence Epidemiology (2020-2034)
• Figure 2: 7MM Fecal Incontinence Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Fecal Incontinence Epidemiology in the United States (2020-2034)
• Figure 4: Fecal Incontinence Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Fecal Incontinence Epidemiology in Germany (2020-2034)
• Figure 6: Fecal Incontinence Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Fecal Incontinence Epidemiology in France (2020-2034)
• Figure 8: Fecal Incontinence Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Fecal Incontinence Epidemiology in Italy (2020-2034)
• Figure 10: Fecal Incontinence Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Fecal Incontinence Epidemiology in Spain (2020-2034)
• Figure 12: Fecal Incontinence Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Fecal Incontinence Epidemiology in the UK (2020-2034)
• Figure 14: Fecal Incontinence Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Fecal Incontinence Epidemiology in Japan (2020-2034)
• Figure 16: Fecal Incontinence Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary